CR10143A - Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer - Google Patents

Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer

Info

Publication number
CR10143A
CR10143A CR10143A CR10143A CR10143A CR 10143 A CR10143 A CR 10143A CR 10143 A CR10143 A CR 10143A CR 10143 A CR10143 A CR 10143A CR 10143 A CR10143 A CR 10143A
Authority
CR
Costa Rica
Prior art keywords
sialic acid
antigens
des
acetyl
antibodies
Prior art date
Application number
CR10143A
Other languages
English (en)
Inventor
R Moe Gregory
Paul Plested Charles
Original Assignee
Childrens Hosp & Res Ct Oak
Frak Boring Fitzgerald
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp & Res Ct Oak, Frak Boring Fitzgerald filed Critical Childrens Hosp & Res Ct Oak
Publication of CR10143A publication Critical patent/CR10143A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

La presente invención proporciona en general composiciones y métodos relacionados con el diagnóstico y/o el tratamiento de cánceres, que tienen un antígeno de ácido siálico des-N-acetilado de superficie celular, por ejemplo, un gangliósido des-N-acetilado y/o una proteína de superficie celular modificada por ácido siático des-N-acetilado.
CR10143A 2005-12-23 2008-07-15 Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer CR10143A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75384705P 2005-12-23 2005-12-23

Publications (1)

Publication Number Publication Date
CR10143A true CR10143A (es) 2008-10-10

Family

ID=38218629

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10143A CR10143A (es) 2005-12-23 2008-07-15 Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer

Country Status (10)

Country Link
EP (1) EP1976554B1 (es)
JP (1) JP5384941B2 (es)
KR (1) KR101462963B1 (es)
AU (1) AU2006331634B2 (es)
BR (1) BRPI0620453A2 (es)
CA (1) CA2634755C (es)
CR (1) CR10143A (es)
EC (1) ECSP088636A (es)
MX (1) MX2008008185A (es)
WO (1) WO2007075921A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008272854B2 (en) 2007-07-03 2014-03-13 Children's Hospital & Research Center At Oakland Inhibitors of polysialic acid de-N-acetylase and methods for using the same
JP5523313B2 (ja) * 2007-07-03 2014-06-18 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸誘導体、製造方法、ならびにがん抗原産生の増強およびターゲティングにおける使用
EP2173759A4 (en) 2007-07-03 2014-01-29 Childrens Hosp & Res Ct Oak OLIGOSIALIC ACID DERIVATIVES, METHODS OF MANUFACTURE AND IMMUNOLOGICAL USES
EP2281004A4 (en) * 2008-04-14 2012-02-15 Proscan Rx Pharma Inc PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
FR2955321B1 (fr) 2010-01-21 2012-02-10 Rhodia Operations Procede d'oxydation d'hydrocarbures
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
CN106102776B (zh) 2014-01-24 2020-02-14 圣安德鲁斯大学董事会 免疫调节化合物
GB201616009D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Treatment and/or prevention of sepsis
GB201616007D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Novel Adjuvants
GB201616006D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Cell modulation
CN112795583A (zh) * 2020-11-16 2021-05-14 上海大学 重组唾液酸外切酶的制备方法、表达基因、重组表达载体及构建方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008874A1 (en) * 1996-08-27 1998-03-05 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
CA2279134A1 (en) * 1999-07-29 2001-01-29 Tianmin Liu Novel strategy for carbohydrate-based therapeutic vaccines
EP1784428A2 (en) * 2004-06-23 2007-05-16 Children's Hospital & Research Center at Oakland Polysaccharide derivatives and uses in induction of an immune response

Also Published As

Publication number Publication date
JP5384941B2 (ja) 2014-01-08
AU2006331634B2 (en) 2013-01-10
KR101462963B1 (ko) 2014-11-19
EP1976554A4 (en) 2010-05-12
EP1976554A2 (en) 2008-10-08
EP1976554B1 (en) 2016-11-16
BRPI0620453A2 (pt) 2011-11-08
JP2009525947A (ja) 2009-07-16
WO2007075921A2 (en) 2007-07-05
CA2634755C (en) 2018-03-27
AU2006331634A1 (en) 2007-07-05
MX2008008185A (es) 2008-11-14
CA2634755A1 (en) 2007-07-05
KR20080091777A (ko) 2008-10-14
ECSP088636A (es) 2008-08-29
WO2007075921A3 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
CR10143A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1123030T1 (el) Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
PA8782201A1 (es) Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos
BRPI0810096A2 (pt) Anticorpo anti-epcam e seus usos
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
CO6351751A2 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
AR054474A1 (es) Formulacion de anticuerpos estables
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
CY1115212T1 (el) Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
CL2008001258A1 (es) Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
EP1708751A4 (en) METHOD OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGEN EXPOSED ON APOPTOTIC TUMOR CELLS
AR071304A1 (es) Anticuerpos anti cd151 (proteina de membrana de la flia. de las tetraspaninas) utiles para el tratamiento de cancer
CR10996A (es) Metodo de tratamiento del cancer mediante administracion de combinaciones de il-18 humana
BRPI0407680A (pt) métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas
BR112014029089A2 (pt) anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2
ATE525401T1 (de) Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene
CL2009000177A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas; linea celular de hibridoma que lo produce; composicion farmaceutica que los comprende; ensayo para determinar la presencia de celulas cancerosas; y uso para tratar tumores.
CL2009000176A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas; linea celular de hibridoma que lo produce; composicion farmaceutica que los comprende; ensayo para determinar la presencia de celulas cancerosas; y su uso para tratar tumores.
CL2009000175A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas; linea celular de hibridoma que los produce; composicion farmaceutica que los comprende; ensayo para determinar la presencia de celulas cancerosas; y su uso para tratar tumores.